PubMed

A randomized comparison of pioglitazone to inhibit restenosis after coronary stenting in patients with type 2 diabetes.

Nishio K, Sakurai M, Kusuyama T, Shigemitsu M, Fukui T, Kawamura K, Itoh S, Konno N, Katagiri T.

Diabetes Care. 2006 Jan;29(1):101-6.PMID: 16373904 [PubMed - indexed for MEDLINE]Related articlesFree article

Comparison of bare metal stent with pioglitazone versus sirolimus-eluting stent for percutaneous coronary intervention in patients with Type 2 diabetes mellitus.

Nishio K, Shigemitsu M, Kodama Y, Konno N, Katagiri T, Kobayashi Y.

Cardiovasc Revasc Med. 2009 Jan-Mar;10(1):5-11.PMID: 19159848 [PubMed - indexed for MEDLINE]Related articles

Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes.

Choi D, Kim SK, Choi SH, Ko YG, Ahn CW, Jang Y, Lim SK, Lee HC, Cha BS.

Diabetes Care. 2004 Nov;27(11):2654-60.PMID: 15505001 [PubMed - indexed for MEDLINE]Related articlesFree article

The effect of pioglitazone on nitric oxide synthase in patients with type 2 diabetes mellitus.

Nishio K, Shigemitsu M, Kodama Y, Itoh S, Konno N, Satoh R, Katagiri T, Kobayashi Y.

J Cardiometab Syndr. 2008 Fall;3(4):200-4.PMID: 19040587 [PubMed - indexed for MEDLINE]Related articles

A prospective, multicenter, randomized trial to assess efficacy of pioglitazone on in-stent neointimal suppression in type 2 diabetes: POPPS (Prevention of In-Stent Neointimal Proliferation by Pioglitazone Study).

Takagi T, Okura H, Kobayashi Y, Kataoka T, Taguchi H, Toda I, Tamita K, Yamamuro A, Sakanoue Y, Ito A, Yanagi S, Shimeno K, Waseda K, Yamasaki M, Fitzgerald PJ, Ikeno F, Honda Y, Yoshiyama M, Yoshikawa J; POPPS Investigators.

JACC Cardiovasc Interv. 2009 Jun;2(6):524-31.PMID: 19539256 [PubMed - indexed for MEDLINE]Related articles

Reduction of neointimal hyperplasia after coronary stenting by pioglitazone in nondiabetic patients with metabolic syndrome.

Katayama T, Ueba H, Tsuboi K, Kubo N, Yasu T, Kuroki M, Saito M, Momomura S, Kawakami M.

Am Heart J. 2007 May;153(5):762.e1-7.PMID: 17452150 [PubMed - indexed for MEDLINE]Related articles

Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus: an intravascular ultrasound scanning study.

Takagi T, Yamamuro A, Tamita K, Yamabe K, Katayama M, Mizoguchi S, Ibuki M, Tani T, Tanabe K, Nagai K, Shiratori K, Morioka S, Yoshikawa J.

Am Heart J. 2003 Aug;146(2):E5.PMID: 12891212 [PubMed - indexed for MEDLINE]Related articles

Effect of rosiglitazone on restenosis after coronary stenting in patients with type 2 diabetes.

Osman A, Otero J, Brizolara A, Waxman S, Stouffer G, Fitzgerald P, Uretsky BF.

Am Heart J. 2004 May;147(5):e23.PMID: 15131558 [PubMed - indexed for MEDLINE]Related articles

Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.

Derosa G, D'Angelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo SA, Montagna L, Gravina A, Ferrari I, Paniga S, Cicero AF.

J Clin Pharm Ther. 2006 Aug;31(4):375-83.PMID: 16882108 [PubMed - indexed for MEDLINE]Related articles

Pioglitazone reduces neointima volume after coronary stent implantation: a randomized, placebo-controlled, double-blind trial in nondiabetic patients.

Marx N, Wöhrle J, Nusser T, Walcher D, Rinker A, Hombach V, Koenig W, Höher M.

Circulation. 2005 Nov 1;112(18):2792-8. Epub 2005 Oct 24.PMID: 16246947 [PubMed - indexed for MEDLINE]Related articlesFree article

Head-to-head comparison of sirolimus- and paclitaxel-eluting stent in the same diabetic patient with multiple coronary artery lesions: a prospective, randomized, multicenter study.

Tomai F, Reimers B, De Luca L, Galassi AR, Gaspardone A, Ghini AS, Ferrero V, Favero L, Gioffrè G, Prati F, Tamburino C, Ribichini F.

Diabetes Care. 2008 Jan;31(1):15-9. Epub 2007 Oct 1.PMID: 17909090 [PubMed - indexed for MEDLINE]Related articlesFree article

Effects of pioglitazone on endothelial function, insulin sensitivity, and glucose control in subjects with coronary artery disease and new-onset type 2 diabetes.

Sourij H, Zweiker R, Wascher TC.

Diabetes Care. 2006 May;29(5):1039-45.PMID: 16644634 [PubMed - indexed for MEDLINE]Related articlesFree article

Combination therapy of pioglitazone with voglibose improves glycemic control safely and rapidly in Japanese type 2-diabetic patients on hemodialysis.

Abe M, Kikuchi F, Kaizu K, Matsumoto K.

Clin Nephrol. 2007 Nov;68(5):287-94.PMID: 18044260 [PubMed - indexed for MEDLINE]Related articles

Association of insulin resistance, hyperleptinemia, and impaired nitric oxide release with in-stent restenosis in patients undergoing coronary stenting.

Piatti P, Di Mario C, Monti LD, Fragasso G, Sgura F, Caumo A, Setola E, Lucotti P, Galluccio E, Ronchi C, Origgi A, Zavaroni I, Margonato A, Colombo A.

Circulation. 2003 Oct 28;108(17):2074-81. Epub 2003 Oct 6.PMID: 14530196 [PubMed - indexed for MEDLINE]Related articlesFree article

Angiographic and clinical outcomes of rosiglitazone in patients with type 2 diabetes mellitus after percutaneous coronary interventions: a single center experience.

Fang CC, Ng Jao YT, Yi-Chen, Yu CL, Chen CL, Wang SP.

Angiology. 2007 Oct-Nov;58(5):523-34.PMID: 18024934 [PubMed - indexed for MEDLINE]Related articles

Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial.

Derosa G, Cicero AF, D'Angelo A, Gaddi A, Ciccarelli L, Piccinni MN, Salvadeo SA, Pricolo F, Ferrari I, Gravina A, Ragonesi PD.

Clin Ther. 2006 May;28(5):679-88. Erratum in: Clin Ther. 2006 Sep;28(9):1483. PMID: 16861090 [PubMed - indexed for MEDLINE]Related articles

Troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with non-insulin dependent diabetes mellitus: a serial intravascular ultrasound study.

Takagi T, Akasaka T, Yamamuro A, Honda Y, Hozumi T, Morioka S, Yoshida K.

J Am Coll Cardiol. 2000 Nov 1;36(5):1529-35.PMID: 11079654 [PubMed - indexed for MEDLINE]Related articles

Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect.

Satoh N, Ogawa Y, Usui T, Tagami T, Kono S, Uesugi H, Sugiyama H, Sugawara A, Yamada K, Shimatsu A, Kuzuya H, Nakao K.

Diabetes Care. 2003 Sep;26(9):2493-9.PMID: 12941708 [PubMed - indexed for MEDLINE]Related articlesFree article

Clinical investigation of the effects of pioglitazone on the improvement of insulin resistance and blood pressure in type 2-diabetic patients undergoing hemodialysis.

Abe M, Okada K, Kikuchi F, Matsumoto K.

Clin Nephrol. 2008 Sep;70(3):220-8.PMID: 18793563 [PubMed - indexed for MEDLINE]Related articles

Efficacy and safety of low-dose pioglitazone after primary coronary angioplasty with the use of bare metal stent in patients with acute myocardial infarction and with type 2 diabetes mellitus or impaired glucose tolerance.

Yokoyama J, Sutoh N, Higuma T, Horiuchi D, Katoh C, Yokota T, Echizen T, Sasaki S, Hanada H, Osanai T, Okumura K.

Heart Vessels. 2007 May;22(3):146-51. Epub 2007 May 21.PMID: 17533517 [PubMed - indexed for MEDLINE]Related articles